Llwytho...
New insights into MicroRNAs involves in drug resistance in diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) accounts for nearly 40% of non-Hodgkin’s lymphoma cases. The combined chemotherapy of rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone (R-CHOP) is considered as the standard therapy for DLBCL; however, nearly half of the patients become refra...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Am J Transl Res |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
e-Century Publishing Corporation
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4731655/ https://ncbi.nlm.nih.gov/pubmed/26885255 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|